media – Page 10 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Zhongke Chuangxing Angel+Exclusive Investment Round in ‘Saiyun Biology’

Recently, Saiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as “Saiyun Biotechnology”), a biotechnology company specializing in the development of international cutting-edge delivery carrier technology and innovative drug therapies, announced the completion of tens of millions of angel+round financing. This round of financing is exclusively invested by Zhongke Chuangxing, and the funds raised will mainly be used to accelerate the development process of the company’s self-developed pipelines. Saiyun Biotechnology is an enterprise dedicated to the research and development of targeted delivery technology and innovative drug therapies. It has successfully developed a biomimetic delivery system with independent intellectual property rights, which is different from mainstream delivery carrier systems. After rational transformation, the system can achieve precise cell delivery of various types of payloads, and has significant advantages in specificity recognition, payload compatibility, protection, and production cost. As an emerging type of delivery system, the research and development progress of “Saiyun Biology” ...
- Source: drugdu
- 108
- April 8, 2025
Hengrui, Baiji, and China Biopharmaceuticals are leading the way, and China’s innovative drugs have entered the era of “billions”

In the wave of global pharmaceutical innovation, China’s innovative pharmaceutical industry is emerging and making great strides forward. From the recent financial reports released by major pharmaceutical companies, it can be seen that in 2024, Hengrui Pharmaceutical, BeiGene, and China Biopharmaceutical will become the leading forces in promoting China’s innovative drugs towards the era of “billions” with outstanding innovation strength and market performance, reflecting the vigorous and upward development trend of China’s innovative drugs. 1. Hengrui Innovative drug revenue exceeds 13.8 billion yuan, accounting for more than half of total sales revenue Hengrui, as the leader in innovative drugs in China, has achieved great success in 2024. According to its annual report released on March 30th, Hengrui achieved a total operating revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit attributable to shareholders of the listed company of 6.337 billion yuan, a significant year-on-year ...
- Source: drugdu
- 126
- April 8, 2025
Recyclable living battery achieves precise blood pressure regulation. Shenzhen team develops “coin-sized” biological battery

Recently, Zhong Chao’s team from the National Key Laboratory of Quantitative Synthetic Biology of the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences (hereinafter referred to as “Shenzhen Advanced Institute”), Liu Zhiyuan’s team from the Neuroengineering Center of the Shenzhen Institute of Advanced Technology, and Wang Renheng’s team from Shenzhen University published their latest research results in Advanced Materials. They used 3D printing living hydrogel technology to successfully develop a micro-portable microbial fuel cell with a diameter of only 20 mm, innovatively integrated a bioelectric stimulation device, and achieved precise regulation of electrophysiology and blood pressure by stimulating neurons, which has great application potential in disease treatment. This research has promoted the development of portable biological devices and expanded the research frontier of living energy materials. Interdisciplinary development of biobatteries that can be recycled In this study, the research team developed an innovative 3D printed living hydrogel material based ...
- Source: drugdu
- 96
- April 8, 2025
Yingen Biotech starts IPO today and is expected to be listed on April 15

Yingen Biotech plans to be officially listed on the Hong Kong Stock Exchange on April 15, and has received support from a lineup of luxurious cornerstone investors including BioNTech. Yingen Biotech was founded in 2019 and focuses on the research and development of antibody-drug conjugates (ADCs) to treat cancer and autoimmune diseases. The company has two core products: DB-1303/BNT323 is an ADC candidate targeting HER2 for the treatment of endometrial cancer and breast cancer. DB-1311/BNT324 is an ADC candidate targeting B7-H3 for the treatment of small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. In addition to its core products, Yingen Bio also has five other ADC drugs in clinical stage, namely DB-1310, DB-1305/BNT325, DB-1312/BGC9074, DB-1419 and DB-2304, with a wide range of indications; two bispecific ADCs (BsADCs): DB-1418/AVZO-1418 and DB-1421, which are expected to enter the clinical stage from 2025 ...
- Source: drugdu
- 118
- April 8, 2025
China’s biomanufacturing begins to use rice to make blood

“Rice makes blood”, a concept that sounds “fairy tale”, has now become a reality in a biopharmaceutical company in Wuhan. Human serum albumin manufactured in this way is not only safer and more environmentally friendly, but also has the advantages of large-scale production and low cost. It is expected to become an important solution to alleviate the shortage of human serum albumin in my country. At present, the human serum albumin product developed using this technology has completed phase III clinical trials and entered the new drug approval process. The team has built an intelligent factory with an annual output of 1 million injections and is building a large-scale production base with an annual output of 12 million injections. https://finance.eastmoney.com/a/202504063365597167.html
- Source: drugdu
- 95
- April 8, 2025
Firmly oppose! China Chamber of Commerce for Import and Export of Medicines and Health Products issued a statement on the so-called “reciprocal tariffs” imposed by the United States

On April 5, China Chamber of Commerce for Import and Export of Medicines and Health Products issued a statement on the so-called “reciprocal tariffs” imposed by the United States. On April 2, 2025, Eastern Time, the US government announced the imposition of so-called “reciprocal tariffs” on all trading partners, including China. Most medical consumables, dressings, medical equipment and its parts, rehabilitation supplies and other products are affected, especially some products are superimposed on the unreasonable tax increase measures of the US government in the past, and the tariffs have reached extremely high levels. The unilateral trade measures of the US government ignore the rules of the World Trade Organization, which will not only seriously affect the production and operation of global pharmaceutical industry companies including China, but also seriously affect the research and development, production and stability of the global pharmaceutical industry supply chain, and damage the health and well-being ...
- Source: drugdu
- 77
- April 8, 2025
CMEF Guangzhou

Organiser: Reed Sinopharm Exhibitions Time: September 26 – 29, 2025 Address: No. 380, Yuejiang Middle Road, Haizhu District, Guangzhou City Exhibition hall: Canton Fair Complex – Pazhou Hall, Guangzhou Product range: Medical Imaging Zone: Radiology products, ultrasound products, nuclear medicine products, molecular imaging, interventional products, etc. Operating Room Zone: Hybrid operating rooms, integrated operating room solutions, surgical instruments, anesthesia machines, ventilators, patient monitors, operating room engineering, surgical lights, pendant systems, etc. In Vitro Diagnostics Zone: Total laboratory solutions, clinical diagnostic equipment, diagnostic reagents, POCT (Point-of-Care Testing), home diagnostic devices, etc. Rehabilitation & Physiotherapy Zone: Rehabilitation equipment, assistive devices, traditional Chinese medicine treatments, physiotherapy equipment, medical high-frequency devices, etc. Orthopedics Zone: Orthopedic implants (joints, trauma, spine), orthopedic surgical instruments and equipment, bone power tools, and other orthopedic-related products. Medical Informatics Zone: System integrators, mobile healthcare, medical management, quality control, clinical hospital information management systems, IT equipment providers (display, printing, storage), ...
- Source: drugdu
- 82
- April 8, 2025
Orthopedic giant Stryker announced the completion of the sale of this business

According to foreign media reports, on April 1, global orthopedic giant Stryker announced that it had completed the sale of its US spinal implant business to Viscogliosi Brothers, LLC, a family investment company focusing on the neuromusculoskeletal field. It is worth noting that the transaction led to the establishment of a new company called VB Spine, LLC (VB Spine), which also marked the official implementation of Stryker’s business restructuring plan announced in January this year. Previously, Stryker stated that in addition to the US market, its international spinal implant business will also be gradually divested. From Stryker’s 2024 financial report, it can be seen that its spinal implant business can no longer help the company’s revenue. The financial report shows that in 2024, its spinal implant business revenue was US$707 million (a year-on-year decrease of 0.7%), of which the US spinal implant business decreased by 2.1% year-on-year. The specific financial ...
- Source: drugdu
- 80
- April 7, 2025
Yangtze River Pharmaceuticals enters the race for Elamod

Recently, the official website of the National Medical Products Administration (NMPA) showed that Yangtze River Pharmaceutical’s Aguratimod tablets, which were applied for as a generic 4 drug, were officially approved for marketing, becoming the second company in China to have its generic drug approved and pass the consistency evaluation. This progress not only marks a further breakthrough for Yangtze River Pharmaceutical in the field of anti-rheumatic diseases, but also provides more treatment options for domestic patients with rheumatoid arthritis. Eguratimod tablets are a new type of disease-modifying antirheumatic drug (DMARDs) that has both anti-inflammatory and immunomodulatory mechanisms. It can inhibit the production of inflammatory factors such as IL-6 and TNF-α, while delaying bone erosion and promoting bone formation. Clinical data show that it can be effective in 2-4 weeks when used in combination with methotrexate, with a patient remission rate of over 60%, and significantly lower liver toxicity and infection ...
- Source: drugdu
- 99
- April 7, 2025
Huadong Medicine, a leader in diabetes, has its domestic application for semaglutide accepted

On the evening of April 1, 2025, Huadong Medicine Co., Ltd. (stock code: 000963.SZ, hereinafter referred to as “Huadong Medicine”) issued an announcement stating that the company’s wholly-owned subsidiary Hangzhou Sino-US Huadong Pharmaceutical Jiangdong Co., Ltd. (hereinafter referred to as “Jiangdong Company”) received the “Acceptance Notice” issued by the National Medical Products Administration (NMPA), and the application for marketing authorization of semaglutide injection was accepted. The indication for this application is blood sugar control in adult patients with type 2 diabetes. In addition, the clinical trial application for the fluid re-management indication of semaglutide injection was approved by NMPA in September 2024, and the first subject was enrolled in the Phase III clinical trial in December 2024. Due to the excellent and popular hypoglycemic and weight loss effects of semaglutide, its biosimilars will face huge market opportunities when they are launched. Semaglutide becomes the “King of GLP-1 Drugs” and has ...
- Source: drugdu
- 94
- April 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.